Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies - Wikidata - awgldk - TriplyDB

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

http://www.wikidata.org/entity/Q36617540

about

Waldenström macroglobulinemia Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature.Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.Cladribine in the treatment of chronic lymphocytic leukemia.Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.Waldenström's macroglobulinemia: a review of therapy.Waldenstrom macroglobulinemia: prognosis and management.Cladribine in indolent non-Hodgkin's lymphoma.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro.

P2860

Q24634076-08582E99-61E3-4503-9699-84398CBDC61D Q28290236-9CEA79CE-6B0A-4FB2-B5EF-6BE1F4953F6F Q30671981-EF733231-B932-4F63-AFE4-D413D489663E Q33337294-25E7BB0B-5B8F-4BAB-8F1E-C97F30801750 Q33337860-B458A890-12B7-4087-95D4-87DB5180CB5B Q34116907-8932392B-E362-4182-A895-0DB922CF91C2 Q34980339-76B75DD5-3FA9-43C8-8943-51DEF00535FB Q35244911-B3B51A7D-D4AA-4F26-9CE3-B371FBC2F756 Q37134422-5E8655B8-8E58-40DE-B0C3-24A8AF04177F Q38594531-886A44C8-7057-47BC-85DD-8B27BFCEDD15 Q39044362-F04715E1-ED74-4674-847F-D01A17E1C59A Q42861257-336C8009-D8C1-48F8-8EC7-69AD2818A74B Q44133294-E15082F3-A8FB-4B9D-B75E-1F125DB7F5F6

P2860

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

http://www.wikidata.org/entity/Q36617540

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@ast

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@en

type

label

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@ast

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@en

prefLabel

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@ast

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@en

P1433

Q36617540-D8566752-34FA-43D0-B94E-E4728F232E7E

P1476

Q36617540-64AF5E9C-95F1-4FB8-8360-D22376268A5C

P2093

Q36617540-08EC20B2-67AD-47E2-8116-2C2FCF1F35BE

Q36617540-25D607D4-1B17-4749-8FA7-F58B6F084FB3

Q36617540-939DDCBF-07A3-44AB-B932-8A1A70A96B21

Q36617540-963130F4-2216-4430-9D5B-0BE66E5998B2

Q36617540-C4A6121F-BF8D-43B2-A02E-470543F82577

Q36617540-D675DC96-1667-451C-811D-C66155D5F51F

P2860

Q36617540-0BBB0591-4F26-4C6E-AC22-985EBC38D3A5

Q36617540-2525F21F-55DF-43B9-8F09-803F5014AD2D

Q36617540-4FFC558E-BF03-4A28-A3D4-D1D715033CCE

Q36617540-55BA592C-DADB-407B-B75C-3E9EBC6A7F2A

Q36617540-5F894020-5F1C-42C2-992F-FF10F694376E

Q36617540-88C872AB-4A18-466E-9CCC-85848211FBD4

Q36617540-902FE4F8-5315-4C79-8351-5783196ABE84

Q36617540-B5DCEECA-CBD1-44A9-B84E-E1DA207332A0

Q36617540-B9A7D9D5-E674-4CAC-9C74-07D2497FAC1E

Q36617540-C68C6B0A-CB6D-41B4-ADA6-E38495E14701

P2888

Q36617540-5FEEAD97-4956-4F60-A7BA-0D29FE531A00

P304

Q36617540-25541543-EB7B-44E6-8395-3A5D72EEAFBC

P31

Q36617540-D4A41C07-E7EA-49DD-B139-E6DF831BFC3E

P356

Q36617540-6D94B2EB-F76D-402B-853F-53EC807D5856

P407

Q36617540-50A23227-CF8F-40E5-9E1B-42B29624FEBF

P433

Q36617540-68D27E55-97AE-4708-895A-5052ACA0FB98

P478

Q36617540-A75ED903-099F-4262-BA2F-3D68D20F86F3

P577

Q36617540-C6047CCD-9E54-45E0-AB83-5E1C0694834F

P5875

Q36617540-56036C1E-74A5-4E24-BD01-A926BECCB5FF

P698

Q36617540-B85DE84D-86F0-4FB2-9DB9-54FFD19695EC

P932

Q36617540-C6C3FC59-7CB3-4CE0-B0F4-6C515D4DCFE7

P356

P1433

British Journal of Cancer

P1476

Cladribine with cyclophosphami ...... mphoproliferative malignancies

@en

P2093

Alberto P

http://www.w3.org/2001/XMLSchema#string

Betticher DC

http://www.w3.org/2001/XMLSchema#string

Guetty-Alberto M

http://www.w3.org/2001/XMLSchema#string

Iten PA

http://www.w3.org/2001/XMLSchema#string

Laurencet FM

http://www.w3.org/2001/XMLSchema#string

Zulian GB

http://www.w3.org/2001/XMLSchema#string

P2860

2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia.

2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.

Cladribine (2-chlorodeoxyadenosine)

Karnofsky memorial lecture. The low-grade non-Hodgkin's lymphomas: challenges and opportunities.

Infectious and immunosuppressive complications of purine analog therapy.

P2888

P304

1215-1219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6690195

http://www.w3.org/2001/XMLSchema#string

P407

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13191974

http://www.w3.org/2001/XMLSchema#string

P698

10098762

http://www.w3.org/2001/XMLSchema#string

P932

2362247

http://www.w3.org/2001/XMLSchema#string